文章摘要
谢燕东,张静瑜,樊晴伶,张义灵,王 成.参苓白术散联合复方谷氨酰胺肠溶胶囊对肠易激综合征患者的肠黏膜屏障功能及5-HT、IFN-γ、IL-8水平的影响[J].,2019,19(22):4269-4272
参苓白术散联合复方谷氨酰胺肠溶胶囊对肠易激综合征患者的肠黏膜屏障功能及5-HT、IFN-γ、IL-8水平的影响
Effects of Shenling Baizhu Powder Combined with Compound Glutamine on Intestinal Mucosal Barrier Function and Levels of 5-HT, IFN-γ and IL-8 in Patients with Irritable Bowel Syndrome
投稿时间:2019-06-06  修订日期:2019-06-28
DOI:10.13241/j.cnki.pmb.2019.22.014
中文关键词: 参苓白术散  复方谷氨酰胺肠溶胶囊  肠易激综合征  肠黏膜屏障功能
英文关键词: Shenling Baizhu Powder  Compound Glutamine  Irritable bowel syndrome  Intestinal mucosal barrier function
基金项目:陕西省自然科学基金项目(20140317)
作者单位E-mail
谢燕东 空军军医大学唐都医院 消化内科 陕西 西安 710038 livegush@163.com 
张静瑜 空军军医大学唐都医院 消化内科 陕西 西安 710038  
樊晴伶 空军军医大学唐都医院 消化内科 陕西 西安 710038  
张义灵 空军军医大学唐都医院 肿瘤科 陕西 西安 710038  
王 成 空军军医大学唐都医院 消化内科 陕西 西安 710038  
摘要点击次数: 0
全文下载次数: 0
中文摘要:
      摘要 目的:探讨参苓白术散联合复方谷氨酰胺肠溶胶囊对肠易激综合征患者的肠黏膜屏障功能及5-羟色胺(5-HT)、γ-干扰素(IFN-γ)、白细胞介素8(IL-8)水平的影响。方法:选取2017年3月至2018年1月的89例肠易激综合征患者。按照随机数表法分为观察组(n=46)和对照组(n=43),对照组采用复方谷氨酰胺肠溶胶囊治疗,观察组采用参苓白术散联合复方谷氨酰胺肠溶胶囊治疗。观察两组治疗疗效,肠黏膜屏障功能(DAO、D-乳酸、细菌内毒素),血清5-HT、IFN-γ、IL-8水平,不良反应发生率。结果:治疗后,观察组总有效率显著高于对照组[93.47%vs 72.09%](P<0.05);中医症状积分显著低于对照组[(2.81±0.42)分vs(5.79±0.74)分](P<0.05);DAO、D-乳酸、细菌内毒素水平均显著低于对照组[(10.02±1.50)U/L vs(11.85±1.98)U/L,(7.18±1.37)mg/L vs(8.56±1.53)mg/L,(0.60±0.08)pg/mL vs(0.75±0.12)pg/mL](P<0.05);血清5-HT、IFN-γ、IL-8水平均显著低于对照组[(351.08±20.93)pg/mL vs(364.12±29.71)pg/mL,(26.95±5.02)pg/mL vs(31.28±6.10)pg/mL,(2.97±0.51)ng/L vs(4.03±0.62)ng/L](P<0.05);不良反应总发生率显著低于对照组 [6.52%(3/46)vs20.93%(9/43)](P<0.05)。结论:参苓白术散联合复方谷氨酰胺肠溶胶囊治疗肠易激综合征患者的临床疗效显著,可改善临床症状,改善肠黏膜屏障功能,及5-HT、IFN-γ、IL-8水平,减轻炎症反应,安全可靠。
英文摘要:
      ABSTRACT Objective: To explore the effects of shenling baizhu powder and combined with compound glutamine on intestinal mucosal barrier function and levels of 5-hydroxytryptamine(5-HT), interferon-γ(IFN-γ) and interleukin-8 (IL-8) in patients with irritable bowel syndrome. Methods: 89 Irritable bowel syndrome who received therapy from March 2017 to January 2018 in our hospital were selected as research objects. According to random number table, those patients were divided into the observation group (n=46) and the control group (n=43). The control group was treated with compound glutamine, while the observation group treated with Shenling Baizhu Powder Combined with compound glutamine. Then the therapeutic efficacy, intestinal mucosal barrier function (DAO, D-lactic acid, ET), serum levels of 5-HT, IFN-gamma and IL-8, incidence of adverse reactions of two groups after treatment were compared. Results: After treatment, the total effective rate of observation group was significantly higher than that of control group (93.47%vs72.09%)(P<0.05). The score of self-appraisal of clinic symptoms was significantly lower than that of the control group[(2.81±0.42)scores vs(5.79±0.74)scores](P<0.05). The levels of DAO, D-lactic acid and ET were significantly lower than those of the control group[(10.02±1.50)U/L vs(11.85±1.98)U/L, (7.18±1.37)mg/L vs(8.56±1.53)mg/L, (0.60±0.08)pg/mL vs(0.75±0.12)pg/mL](P<0.05). Serum levels of 5-HT, IFN-gamma and IL-8 were significantly lower than those of the control group[(351.08±20.93)pg/mL vs(364.12±29.71)pg/mL, (26.95±5.02)pg/mL vs(31.28±6.10)pg/mL, (2.97±0.51)ng/L vs(4.03±0.62)ng/L](P<0.05). The total incidence of adverse reactions was significantly lower than that in the control group [6.52%(3/46) vs 20.93%(9/43)](P<0.05). Conclusion: Shenling Baizhu Powder combined with compound glutamine in the treatment of irritable bowel syndrome has a significant clinical effect. It can improve clinical symptoms, restore intestinal mucosal barrier function, and 5-HT, IFN-gamma, IL-8 levels, alleviate inflammation, and it is safe and reliable.
查看全文   查看/发表评论  下载PDF阅读器
关闭